ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Shareholders meeting

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Apr 07, 2022 3:54pm

107 Views

Post# 34585621

RE:RE:Shareholders meeting

M101 wrote: Deadwood aside, I like the new quorum requirement and the virtual format. Also think the today's corporate overview is worth a careful look.

Page 9. The table that shows the little arrow almost extending to Ph1 trials for PMN....that's the only thing that matters to me at this point.

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs